METHODS AND SYSTEMS FOR GENETIC ANALYSIS OF FETAL NUCLEATED RED BLOOD CELLS

• US 20100159506A1
• Filed: 07/27/2009
• Published: 06/24/2010
• Est. Priority Date: 07/25/2008
• Status: Abandoned Application

• Current Assignee: Cellscape Corporation
• Original Assignee: Cellscape Corporation
• Inventors: Brody, Michael D., Parikh, Bhairavi, Halderman, Jonathan D., Balasubramanyam, Vivek, Stone, James
• Application Number:
  US12/509,945
• Publication Number:
  US 20100159506A1
• Time in Patent Office: Days
• US Class Current: 435/39
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

Methods for determining genetic status of a fetus from a sample of maternal blood comprise enriching nucleated red blood cells in the sample, including both fetal and maternal nucleated red blood cells. The nucleated red blood cells are then differentiated from all other blood cells in the enriched sample, and the nucleated red blood cells genetically screened to determine the genetic status. The nucleated red blood cells may be differentiated by immobilizing all enriched blood cells on a solid phase and locating the nucleated red blood cells for interrogation. Optionally, the nucleated red blood cells may be sorted and separated from other enriched blood cells in a liquid phase.

Claims

1. A method for determining genetic status of a fetus, said method comprising;

providing a sample of maternal blood;

enriching nucleated red blood cells including both fetal and maternal nucleated red blood cells in the maternal blood sample;

differentiating the nucleated red blood cells from all other blood cells in the enriched sample; and

screening at least a portion of the differentiated nucleated red blood cells for a genetic status which may be possessed by the fetus but not by the mother.

2. The method of claim 1, wherein the genetic status comprises a genetic .abnormality unique to the fetus.

3. The method of claim 2, wherein the genetic abnormality comprises a chromosomal abnormality.

4. The method of claim 3, wherein the chromosomal abnormality is aneuploidy.

5. The method of claim 2, wherein the genetic abnormality comprises a single gene disorder.

6. The method of claim 1, wherein the genetic status comprises the presence of a Y chromosome which determines gender of the fetus.

7. The method of claim 1, wherein enriching comprises increasing the concentration of fetal and maternal nucleated red blood cells in the enriched sample by at least 10 fold over the concentration in the sample.

8. The method of claim 1, wherein enriching comprises selectively modifying the density of the non-nucleated red blood cells and separating non-nucleated red blood cells from nucleated red blood cells based on density.

9. The method of claim 8, wherein modifying the density comprises selectively lysing non-nucleated red blood cells.

10. The method of claim 8, wherein modifying the density of the non-nucleated red blood cells comprises increasing the density with a density modification agent.

11. The method of claim 8, wherein the non-nucleated red blood cells are separated in a density gradient.

12. The method of claim 1, wherein enriching comprises sphering the non-nucleated red blood cells and filtering them from the sample based on shape.

13. The method of claim 1, wherein differentiating comprises immobilizing blood cells including fetal and maternal nucleated red blood cells from the enriched sample on a substrate.

14. The method of claim 13, wherein immobilizing comprises flowing at least a portion of the blood sample over a substrate and removing liquid components of the blood to affix a layer of blood cells to the substrate.

15. The method of claim 14, wherein flowing comprises drawing the blood sample into a capillary space formed over the substance.

16. The method of claim 13, further comprising identifying two locations of the immobilized nucleated red blood cells on the substrate.

17. The method of claim 16, wherein identifying the locations comprises optically scanning the substrate and identifying nucleated red blood cells based on visual characteristics.

18. The method of claim 17, further comprising recording the coordinates of those locations having identified nucleated red blood cells so that said locations can be subsequently interrogated based on the coordinates.

19. The method of claim 17, wherein further comprising labeling the identified nucleated red blood cells with a detectable label so that the nucleated red blood cells may be subsequently screened based on presence of the label without screening other immobilized blood cells.

20. The method of claim 17, wherein the identified nucleated red blood cells are genetically screened substantially immediately after they are identified.

21. The method of claim 16, further comprising transferring nucleated red blood cells from the identified locations to another receptacle for analysis.

22. The method of claim 20, wherein the transferred nucleated red blood cells are immobilized on a second substrate for analysis.

23. The method of claim 20, wherein the transferred nucleated red blood cells are collected and suspended in a liquid for analysis.

24. The method of claim 1, wherein differentiating comprises sorting the enriched cells to separate nucleated red blood cells from all other blood cells and collecting the separated nucleated red blood cells in a liquid phase.

25. The method of claim 24, further comprising immobilizing the separated nucleated red blood cells on a second substrate, wherein screening is performed on the immobilized nucleated red blood cells.

26. The method of claim 24, wherein screening is performed on the nucleated red blood cells in the liquid phase.

27. The method of claim 17, wherein optically scanning comprises directing a light beam at a wavelength which is strongly absorbed by hemoglobin at a plurality of immobilized blood cells, wherein those blood cells which absorb said light in a ring around a nucleus are determined to be nucleated red blood cells.

28. The method of claim 27, further comprising adding a contrast agent to the cells to increase contrast between the nucleus and the hemoglobin.

29. The method of claim 27, wherein light absorbance is determined by phase contrast microscopy.

30. The method of claim 27, further comprising directing light at multiple wavelengths wherein at least one wavelength is outside the range of hemoglobin absorbance to act as a reference.

31. The method of claim 30, wherein a first absorptive wavelength is at 415 nm, a second absorptive wavelength is at 530 nm, and a third reference wavelength is in the red or infrared region, wherein three sequential images are taken and analyzed to remove extraneous sources of absorbance.

32. The method of claim 27, further comprising detecting cell nuclei independent of hemoglobin absorbance.

33. The method of claim 32, wherein the cells are scanned with 260 nm light to detect nuclei.

34. The method of claim 14, wherein screening comprises probing all cells immobilized on the substrate simultaneously.

35. The method of claim 1, wherein differentiating comprises separating the fetal and maternal nucleated red blood cells from other blood cells in the sample to produce a liquid phase consisting primarily of nucleated red blood cells.

36. The method of claim 35, wherein screening comprises probing all cells in the liquid phase fraction simultaneously.

37. The method of claim 35, further comprising transferring at least some of the nucleated red blood cells from the liquid phase to a substrate and immobilizing said transferred cells on the substrate.

38. The method of claim 1, wherein the genetic status is determined by fluorescent in situ hybridization (FISH).

39. The method of claim 30, wherein the hybridization is performed under a partial vacuum.

40. The method of claim 1, wherein the genetic status is determined by polymerase/ligase chain reaction (PCR/LCR).

41. The method of claim 1, wherein the genetic status of at least about 100 nucleated red blood cells are determined.

42. The method of claim 1, wherein the fetal nucleated red blood cells and the maternal nucleated red blood cells are not distinguished.

43. The method of claim 1, wherein the chromosomal status is determined during the first trimester of pregnancy.

44. A method for identifying an increased risk of abnormal pregnancy in a pregnant female, said method comprising;

providing a sample of maternal blood;

enriching nucleated red blood cells including both fetal and maternal nucleated red blood cells in the maternal blood sample;

differentiating the nucleated red blood cells from all other blood cells in the enriched sample; and

determining the number of nucleated red blood cells in the sample, wherein an elevated number of nucleated red blood cells in comparison to a threshold number indicates an increased risk of abnormal pregnancy in the pregnant female.

45. The method of claim 44, wherein the fetal nucleated red blood cells and the maternal nucleated red blood cells are not distinguished.

46. The method of claim 44, wherein the number of nucleated red blood cells is determined during the first trimester of pregnancy.

47. The method of claim 44, wherein the abnormal pregnancy is preeclampsia.